iX Biopharma Ltd. (SGX: 42C)

iX Biopharma Ratios and Metrics

Market cap in millions SGD. Fiscal year is July - June.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 8, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Market Capitalization	20	22	70	122	167	162
Market Cap Growth	-68.05%	-68.05%	-43.05%	-26.84%	3.17%	-1.31%
Enterprise Value	24	22	62	111	162	156
PS Ratio	3.74	3.74	11.79	8.51	95.91	164.69
PB Ratio	5.13	5.13	4.40	6.20	14.29	15.95
P/FCF Ratio	-3.26	-3.26	-8.35	41.89	-18.79	-17.44
P/OCF Ratio	-3.40	-3.40	-9.10	39.21	-20.04	-19.50
EV/Sales Ratio	3.97	3.73	10.51	7.70	92.74	157.93
EV/EBITDA Ratio	-3.13	-3.13	-6.87	96.40	-15.00	-14.79
EV/EBIT Ratio	-2.96	-2.96	-6.51	221.09	-14.16	-13.94
EV/FCF Ratio	-3.47	-3.25	-7.44	37.89	-18.17	-16.72
Debt / Equity Ratio	1.20	1.20	0.27	0.22	0.36	0.39
Debt / EBITDA Ratio	-	-	-	2.91	-	-
Debt / FCF Ratio	-0.76	-0.76	-0.52	1.51	-0.48	-0.42
Asset Turnover	0.30	0.30	0.22	0.61	0.10	0.05
Inventory Turnover	4.20	4.20	3.86	2.09	2.14	1.81
Quick Ratio	0.65	0.65	1.34	1.98	2.19	2.14
Current Ratio	0.89	0.89	1.53	2.14	2.55	2.47
Return on Equity (ROE)	-106.91%	-106.91%	-54.02%	-29.24%	-75.27%	-68.47%
Return on Assets (ROA)	-23.69%	-23.69%	-22.32%	1.32%	-39.86%	-31.95%
Return on Capital (ROIC)	-31.51%	-31.51%	-26.91%	1.56%	-47.57%	-36.32%
Earnings Yield	-48.44%	-48.44%	-13.79%	-3.76%	-4.92%	-6.47%
FCF Yield	-30.64%	-30.64%	-11.98%	2.39%	-5.32%	-5.74%
Buyback Yield / Dilution	-0.33%	-0.33%	-2.51%	-7.60%	-7.13%	-0.54%
Total Shareholder Return	-0.33%	-0.33%	-2.51%	-7.60%	-7.13%	-0.54%

Source: S&P Capital IQ. Standard template. Financial Sources.